Clinical trials: Allogeneic Stem Cell Transplant
Acute Myeloblastic Leukemia
Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen
Although transplant results for AML in complete remission (CR) at the time of transplant have improved, transplant results for non-remission AML have been quite poor.
- Trial name
- CloBu4 (NCT01457885)
- Testing
- Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant
- Where
- 12 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- University of Michigan Rogel Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
This pilot phase II trial studies how well giving donor T cells after donor stem cell transplant works in treating patients with hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Trial name
- NCT01839916
- Testing
- therapeutic allogeneic lymphocytes, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- University of Chicago
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab
This is a single arm, open-label, Phase 1b study of pembrolizumab for patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL) whose disease has relapsed after receiving…
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
- Trial name
- NCT03286114
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Michigan Rogel Cancer Center
Poor Graft Function
Decitabine for Poor Graft Function Post Allo-HSCT
This randomized trial aims at validating the efficacy and safety of low-dose decitabine for PGF post allo-HSCT.
- Trial name
- NCT05907499
- Testing
- Decitabine, Granulocyte Colony-Stimulating Factor, Thrombopoietin Receptor Agonist
- Where
- China
- Volunteers
- 76 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Lymphoma
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn if adding Zevalin (ibritumomab tiuxetan) to low-intensity chemotherapy (the combination of rituximab, bendamustine, and fludarabine), followed by an allogeneic stem cell…
- Trial name
- NCT01490723
- Testing
- Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Graft-versus-Host Disease
Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)
The goal of this clinical research study is to learn if Revlimid® (lenalidomide), along with standard-of-care steroid treatment you are already receiving, can help to control Chronic Graft-Versus-Host Disease (cGVHD).
- Trial name
- NCT00675441
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Ruxolitinib Prior to Transplant in Patients With Myelofibrosis
The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing another person's hematopoietic stem cells…
- Conditions
- Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis
- Trial name
- NCT01790295
- Testing
- Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
- Where
- 8 sites in United States, Canada and 1 more
- Volunteers
- 21 people
- Sponsor
- John Mascarenhas
Leukemia, Myelodysplastic Syndromes
Busulfan, Etoposide, and Total-Body Irradiation in Treating Patients Undergoing Donor Stem Cell or Bone Marrow Transplant for Advanced Hematologic Cancer
RATIONALE: Giving chemotherapy and total-body irradiation before a donor stem cell transplant or a donor bone marrow transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from…
- Trial name
- NCT00534430
- Testing
- busulfan, cyclosporine, etoposide
- Volunteers
- 30 people
- Sponsor
- City of Hope Medical Center
Graft vs. Host Disease
Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease
To determine whether treatment with ustekinumab will alter the ratio of T Regulatory Cell (Treg)/total cluster of differentiation 4 (CD4)+ cells in peripheral blood at day 30 post-hematopoietic cell transplantation (HCT).
- Trial name
- Ustekinumab (NCT01713400)
- Testing
- Ustekinumab, Tacrolimus (TAC), Sirolimus
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lymphoid Leukemia, Acute, Myeloid Malignancy
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
This pilot study is being conducted to treat patients who have a certain type of malignancy (lymphoid or myeloid) with immune effector cells after a T-cell depleted allogeneic hematopoietic cell transplantation (TCD HSCT).
- Conditions
- Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
- Trial name
- NCT05350163
- Testing
- T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Guenther Koehne
Lymphoma, B-Cell, Lymphoma, Non-hodgkins
T Cells Expressing a Fully-human AntiCD19 Chimeric Antigen Receptor for Treating B-cell Malignancies
Background: The immune system fights infection and can affect cancer cells. T cells are white blood cells that are a major part of the immune system. T cells can destroy tumors.
- Trial name
- NCT02659943
- Testing
- Anti-cluster of differentiation 19 (CD19)-Chimeric Antigen Receptor (CAR) T cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
Background: The mainstay of therapy for newly diagnosed multiple myeloma patients remains systemic chemotherapy. Although partial remissions of up to 60% are obtained with conventional regimens, multiple myeloma is essentially an…
- Trial name
- NCT00006184
- Testing
- Myeloma Immunoglobulin Idiotype Vaccine, Bortezomib, Cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
This phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214
- Trial name
- NCT01760655
- Testing
- Fludarabine phosphate, Busulfan, Total-Body Irradiation
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
This randomized clinical trial studies different chemotherapies in treating patients with myelodysplastic syndrome before donor stem cell transplant.
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome
- Trial name
- ICT-HCT (NCT01812252)
- Testing
- Azacitidine (AZC), Decitabine, Quality-of-Life Assessment
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, B-cell, Lymphoma, Non-Hodgkin
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
The purpose of this study is to determine if double autologous then allogeneic hematopoietic cell transplant may offer an improved treatment option for patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are not…
- Conditions
- Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL), Malignant Lymphoma, Non-Hodgkin
- Trial name
- NCT00482053
- Testing
- Autologous hematopoietic stem cell transplantation (auto-HSCT), Allogeneic hematopoietic stem cell transplantation (allo-HSCT), Total lymphoid irradiation (TLI)
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Stanford University
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
This phase II trial studies how well clofarabine and melphalan before a donor stem cell transplant works in treating patients with a decrease in or disappearance of signs and symptoms of myelodysplasia or acute leukemia (disease…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Myelodysplastic Syndrome
- Trial name
- NCT01885689
- Testing
- clofarabine, melphalan, allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- City of Hope Medical Center
Antifungal Prophylaxis of Invasive Fungal Infections
Voriconazole Versus Itraconazole In Primary Prophylaxis Of Invasive Fungal Infection (IFI) In Subjects With Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
Study is to compare antifungal prophylaxis of Voriconazole and Itraconazole in subjects who have had a Stem Cell Transplant. The success of the end point will be measured using evidence of Infection, drug compliance and survival.
- Trial name
- IMPROVIT (NCT00289991)
- Testing
- Itraconazole, Vfend - voriconazole
- Where
- 49 sites in Canada, Czechia and 10 more
- Volunteers
- 489 people
- Sponsor
- Pfizer
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
This phase II trial studies how well T cell depleted donor peripheral blood stem cell transplant works in preventing graft-versus-host disease in younger patients with high risk hematologic malignancies.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Undifferentiated Leukemia
- Trial name
- NCT01858740
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Fludarabine Phosphate, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML)
Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
The purpose of this study is to learn if 5'-Azacitidine will help to lower the risk of the disease coming back after a stem cell transplant in patients with MDS and AML.
- Trial name
- NCT01995578
- Testing
- low dose 5'-azacitidine
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- Memorial Sloan Kettering Cancer Center